Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial

Inclusion Criteria: 1. Participant must be 2-\<18 years of age at the time of signing the informed consent. 2. Fulfilment of the International League of Associations for Rheumatology (ILAR) classification criteria for non-systemic Juvenile Idiopathic Arthritis (JIA). 3. Inactive disease for ≥12 months documented at a minimum of 2 consecutive visits and documented inactive disease according to Wallace criteria at inclusion, and no active uveitis for ≥24 months. 4. Stable treatment with methotrexate and Tumor Necrosis Factor inhibitor (TNFi) for ≥6 months. Weight adjustments permitted. 5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). 6. Male participants: No contraceptive measures necessary. 7. Female participants: contraception guidance for women of childbearing potential (WOCP). Exclusion Criteria: 1. Chronic widespread pain syndrome 2. Major comorbidity including uncontrolled infectious, neurological or mental disease, malignant disease, severe heart failure, severe renal failure, active ulcus ventriculi, and uncontrolled diabetes mellitus. 3. Use of oral, intra-articular, intramuscular or intravenous corticosteroids due to JIA less than 12 months prior to randomization. 4. Participating in an ongoing clinical randomized study.. 5. Drug/alcohol abuse which hampers adherence to the study protocol as based on the investigators judgement. 6. Language barriers that hamper adherence to the study protocol. 7. Pregnancy or breastfeeding. 8. Any condition that in the view of the investigator would suggest that the patient is unable to comply with the study protocol and procedures. 9. Unwillingness to use safe contraception for sexually active WOCP.